Page 245 - The Memory Program How to Prevent Memory Loss and Enhance Memory Power

Page 234

Slaven, L., Lee, C. Mood and symptom reporting among middle-aged women: the relationship between menopausal
status, hormone replacement therapy, and exercise participation. Health Psychology 16:203–208, 1997.

Slotten, H. A., Krekling, S. Does melatonin have an effect on cognitive performance? Psychoneuroendocrinology
21:673–680, 1996.

Small, G. W., La Rue, A., Komo, S., Kaplan, A., Mandelkern, M. A. Predictors of cognitive change in middle-aged and
older adults with memory loss. American Journal of Psychiatry 152:1757–1764, 1995.

Snowdon, D. A., Griener, L. H., Mortimer, J. A., Riley, K. P., Greiner, P. A., Markesbery, W. R. Brain infarction and the
clinical expression of Alzheimer's disease: the nun study. Journal of the American Medical Association 277:813 –817,
1997.

Snowdon, D. A., Kemper, S.J., Mortimer, J. A., Greiner, L. H., Wekstein, D. R., Markesbery, W. R. Linguistic ability in
early life and cognitive function and Alzheimer's disease in late life. Findings from the nuns study. Journal of the
American Medical Association 275:528–532, 1996.

Socci, D.J., Crandall, B. M., Arendash, G. W. Chronic antioxidant treatment improves the cognitive performance of aged
rats. Brain Research 693:88 –94, 1995.

Solfrizzi, V., Panza, F., Torres, F., Mastroianni, F., Del Parigi, A., Venezia, A., Capurso, A. High monounsaturated fatty
acids intake protects against age -related cognitive decline. Neurology 52:1563–1569, 1999.

Solomon, P. R., Hirschoff, A., Kelly, B., Relin, M., Brush, M., DeVeaux, R. D., Pendlebury, W. W. A 7-minute
neurocognitive screening battery highly sensitive to Alzheimer's disease. Archives of Neurology 55:349–355, 1998.

Stern, Y, Gurland, B., Tatemichi, T. K., Tang, M. X., Wilder, D., Mayeux, R. Influence of education and occupation on
the incidence of Alzheimer's disease. Journal of the American Medical Association 271:1004–1010, 1994.

Stern, Y., Sano, M., Mayeux, R. Long-term administration of oral physostigmine in Alzheimer's disease. Neurology
38:1837–1841, 1988.

Stoll, S., Hafner, U., Pohl, W. E., Muller, W. E. Age-related memory decline and longevity under treatment with
selegiline. Life Sciences 55:2155–2163, 1994.

Suhr, J., Tranel, D., Wefel, J., Barrash, J. Memory performance after head injury: contributions of malingering, litigation
status, psychological factors, and medication use. Journal of Clinical and Experimental Neuropsychology 19:500 –514,
1997.

Summers, W. K., Majovski, L. V., Marsh, G. M., Tachiki, K., Kling, A. Oral tetrahydroaminoacridine in long-term
treatment of senile dementia, Alzheimer type. New England Journal of Medicine 315:1241–1245, 1986.

Sunderland, A., Stewart, F. M., Sluman, S. M. Adaptation to cognitive deficit? An exploration of apparent dissociations
between everyday memory and test performance late after stroke. British Journal of Clinical Psychology 35:463–476,
1996.

Tang, M. X., Jacobs, D., Stern, Y., Marder, K., Schofield, P., Gurland, B., Andrews, H., Mayeux, R. Effect of oestrogen
during menopause on risk and age at onset of Alzheimer's disease. Lancet 348:429–432, 1996.

Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., Ding, C. A 5-month, randomized, placebo-
controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54:2269–2276, 2000.

Thal, L.J., Carta, A., Clarke, W. R., Ferris, S. H., Friedland, R. P., Peterson, R. C., Pettegrew, J. W., Pfeiffer, E., Raskind,
M. A., Sano, M., Tuszynski, M. H., Woolson, R. F. A 1-year multicenter placebo-controlled study of acctyl -l-carnitine
in patients with Alzheimer's disease. Neurology 47:705 –711, 1996.